Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study

Figures & data

Table I.  Inclusion criteria.

• Biopsy proven locally advanced prostate cancer (clinical stage T3/T4 with any Gleason score and serum PSA or clinical stage T2 and Gleason score >7 and/serum PSA > 10 ng/ml)

• Patient with a life expectancy of at least 2 years

• Patients under treatment for concurrent disease will be eligible if the medical condition will neither interfere with the process of the treatment nor the analysis

• No prior radical prostatectomy or cryosurgery for prostate cancer

• No prior pelvic RT or orchiectomy

• No previous chemotherapy for malignancy within five years

• No previous or concurrent invasive cancers other than superficial non-melanomatous skin cancers unless disease free for at least five years

• All patients must have signed an informed consent form prior to the registration on the study.

Table II.  Patient characteristics.

No. of patients	144
Median age (yrs) (range)	3 (42–86)
Race (white)	144
Clinical stage
T2b	21
T3	116
T4	7
Gleason grade
Not graded	11
4	3
5	9
6	45
7	32
8	22
9	16
10	6
Radiotherapy dose (Gy)
70	9
72	10
74	95
76	30
No. of hyperthermia treatments
1	3
2	4
3	12
4	121
5	3
8	1
Median follow up (months)	51.7
Range (months)	10–86

Figure 1. Overall survival. Cumulative proportion surviving (Kaplan–Meier method).

Figure 2. Progression free survival (biochemical relapse). Cumulative proportion surviving (Kaplan–Meier method). T2 vs. T3 vs. T4